Glucagon Like Peptide-1 (GLP-1) Agonists Market Report

Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size, Status and Forecast 2014-2026

  • POSTDATE：Jun 20, 2020
  • PAGES：211
  • REPORT CODE：GMM565328
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The Glucagon Like Peptide-1 (GLP-1) Agonists market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 5.0% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Segmentations:

    By Player:

    • AstraZeneca

    • Eli Lily

    • Bristol-Myers Squibb

    • GSK

    • Amylin

    • Sanofi

    • Novo Nordisk

    By Type:

    • Exenatied

    • Liraglutide

    • Lixisenatide

    • Albiglutide

    • Dulaglutide

    By End-User:

    • Hospital

    • Pharmacy

    • Others

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Glucagon Like Peptide-1 (GLP-1) Agonists Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate of Exenatied from 2014 to 2026

    • 1.3.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate of Liraglutide from 2014 to 2026

    • 1.3.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate of Lixisenatide from 2014 to 2026

    • 1.3.4 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate of Albiglutide from 2014 to 2026

    • 1.3.5 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate of Dulaglutide from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate of Hospital from 2014 to 2026

    • 1.4.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate of Pharmacy from 2014 to 2026

    • 1.4.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate of Others from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Glucagon Like Peptide-1 (GLP-1) Agonists Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Glucagon Like Peptide-1 (GLP-1) Agonists by Major Types

      • 3.4.1 Market Size and Growth Rate of Exenatied

      • 3.4.2 Market Size and Growth Rate of Liraglutide

      • 3.4.3 Market Size and Growth Rate of Lixisenatide

      • 3.4.4 Market Size and Growth Rate of Albiglutide

      • 3.4.5 Market Size and Growth Rate of Dulaglutide

    4 Segmentation of Glucagon Like Peptide-1 (GLP-1) Agonists Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Glucagon Like Peptide-1 (GLP-1) Agonists by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Hospital for Construction

      • 4.4.2 Market Size and Growth Rate of Pharmacy for Construction

      • 4.4.3 Market Size and Growth Rate of Others for Construction

    5 Market Analysis by Major Regions

    • 5.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Production Analysis by Top Regions

    • 5.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Analysis by Top Regions

    • 5.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany Glucagon Like Peptide-1 (GLP-1) Agonists Production, Import, Consumption and Export Analysis

      • 5.3.2 UK Glucagon Like Peptide-1 (GLP-1) Agonists Production, Import, Consumption and Export Analysis

      • 5.3.3 France Glucagon Like Peptide-1 (GLP-1) Agonists Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy Glucagon Like Peptide-1 (GLP-1) Agonists Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain Glucagon Like Peptide-1 (GLP-1) Agonists Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland Glucagon Like Peptide-1 (GLP-1) Agonists Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia Glucagon Like Peptide-1 (GLP-1) Agonists Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland Glucagon Like Peptide-1 (GLP-1) Agonists Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Glucagon Like Peptide-1 (GLP-1) Agonists Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) Glucagon Like Peptide-1 (GLP-1) Agonists Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) Glucagon Like Peptide-1 (GLP-1) Agonists Production, Import, Consumption and Export Analysis

    6 Product Circulation of Glucagon Like Peptide-1 (GLP-1) Agonists Market among Top Countries

    • 6.1 Top 5 Export Countries in Glucagon Like Peptide-1 (GLP-1) Agonists Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Glucagon Like Peptide-1 (GLP-1) Agonists Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Glucagon Like Peptide-1 (GLP-1) Agonists Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Glucagon Like Peptide-1 (GLP-1) Agonists Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Glucagon Like Peptide-1 (GLP-1) Agonists Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Glucagon Like Peptide-1 (GLP-1) Agonists Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis

    • 7.1 Germany Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis by Major Types

    • 7.2 Germany Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis by Major End-Users

    8. UK Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis

    • 8.1 UK Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis by Major Types

    • 8.2 UK Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis by Major End-Users

    9. France Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis

    • 9.1 France Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis by Major Types

    • 9.2 France Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis by Major End-Users

    10. Italy Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis

    • 10.1 Italy Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis by Major Types

    • 10.2 Italy Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis by Major End-Users

    11. Spain Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis

    • 11.1 Spain Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis by Major Types

    • 11.2 Spain Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis by Major End-Users

    12. Poland Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis

    • 12.1 Poland Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis by Major Types

    • 12.2 Poland Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis by Major End-Users

    13. Russia Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis

    • 13.1 Russia Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis by Major Types

    • 13.2 Russia Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis by Major End-Users

    14. Switzerland Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis

    • 14.1 Switzerland Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis by Major Types

    • 14.2 Switzerland Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis by Major End-Users

    15. Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis

    • 15.1 Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis by Major Types

    • 15.2 Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis by Top Countries

      • 16.3.1 Denmark Glucagon Like Peptide-1 (GLP-1) Agonists Market Volume and Growth Rate

      • 16.3.2 Finland Glucagon Like Peptide-1 (GLP-1) Agonists Market Volume and Growth Rate

      • 16.3.3 Norway Glucagon Like Peptide-1 (GLP-1) Agonists Market Volume and Growth Rate

      • 16.3.4 Sweden Glucagon Like Peptide-1 (GLP-1) Agonists Market Volume and Growth Rate

      • 16.3.6 Iceland Glucagon Like Peptide-1 (GLP-1) Agonists Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis by Top Countries

      • 17.3.1 Belgium Glucagon Like Peptide-1 (GLP-1) Agonists Market Volume and Growth Rate

      • 17.3.2 Netherlands Glucagon Like Peptide-1 (GLP-1) Agonists Market Volume and Growth Rate

      • 17.3.3 Luxembourg Glucagon Like Peptide-1 (GLP-1) Agonists Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) Glucagon Like Peptide-1 (GLP-1) Agonists Landscape Analysis by Top Countries

      • 18.3.1 Estonia Glucagon Like Peptide-1 (GLP-1) Agonists Market Volume and Growth Rate

      • 18.3.2 Latvia Glucagon Like Peptide-1 (GLP-1) Agonists Market Volume and Growth Rate

      • 18.3.3 Lithuania Glucagon Like Peptide-1 (GLP-1) Agonists Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 AstraZeneca

      • 19.1.1 AstraZeneca Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 Eli Lily

      • 19.2.1 Eli Lily Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 Bristol-Myers Squibb

      • 19.3.1 Bristol-Myers Squibb Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 GSK

      • 19.4.1 GSK Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 Amylin

      • 19.5.1 Amylin Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 Sanofi

      • 19.6.1 Sanofi Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 Novo Nordisk

      • 19.7.1 Novo Nordisk Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    The List of Tables and Figures (Totals 92 Figures and 183 Tables)

    • Figure Product Picture

    • Figure Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate of Exenatied Market, 2015 - 2026 (USD Million)

    • Figure Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate of Liraglutide Market, 2015 - 2026 (USD Million)

    • Figure Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate of Lixisenatide Market, 2015 - 2026 (USD Million)

    • Figure Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate of Albiglutide Market, 2015 - 2026 (USD Million)

    • Figure Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate of Dulaglutide Market, 2015 - 2026 (USD Million)

    • Figure Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate of Hospital from 2014 to 2026

    • Figure Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate of Pharmacy from 2014 to 2026

    • Figure Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate of Others from 2014 to 2026

    • Figure Germany Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

    • Figure UK Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

    • Figure France Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

    • Figure Finland Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

    • Figure Norway Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Glucagon Like Peptide-1 (GLP-1) Agonists Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Glucagon Like Peptide-1 (GLP-1) Agonists

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Glucagon Like Peptide-1 (GLP-1) Agonists by Different Types from 2014 to 2026

    • Table Consumption Share of Glucagon Like Peptide-1 (GLP-1) Agonists by Different Types from 2014 to 2026

    • Figure Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate of Exenatied Market, 2015 - 2026 (USD Million)

    • Figure Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate of Liraglutide Market, 2015 - 2026 (USD Million)

    • Figure Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate of Lixisenatide Market, 2015 - 2026 (USD Million)

    • Figure Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate of Albiglutide Market, 2015 - 2026 (USD Million)

    • Figure Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate of Dulaglutide Market, 2015 - 2026 (USD Million)

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Glucagon Like Peptide-1 (GLP-1) Agonists by Different End-Users from 2014 to 2026

    • Table Consumption Share of Glucagon Like Peptide-1 (GLP-1) Agonists by Different End-Users from 2014 to 2026

    • Figure Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate of Hospital from 2014 to 2026

    • Figure Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate of Pharmacy from 2014 to 2026

    • Figure Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Rate of Others from 2014 to 2026

    • Table Europe Glucagon Like Peptide-1 (GLP-1) Agonists Production by Major Regions

    • Table Europe Glucagon Like Peptide-1 (GLP-1) Agonists Production Share by Major Regions

    • Figure Europe Glucagon Like Peptide-1 (GLP-1) Agonists Production Share by Major Countries and Regions in 2014

    • Table Europe Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Major Regions

    • Table Europe Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Share by Major Regions

    • Table Germany Glucagon Like Peptide-1 (GLP-1) Agonists Production, Import, Consumption and Export Analysis

    • Table UK Glucagon Like Peptide-1 (GLP-1) Agonists Production, Import, Consumption and Export Analysis

    • Table France Glucagon Like Peptide-1 (GLP-1) Agonists Production, Import, Consumption and Export Analysis

    • Table Italy Glucagon Like Peptide-1 (GLP-1) Agonists Production, Import, Consumption and Export Analysis

    • Table Spain Glucagon Like Peptide-1 (GLP-1) Agonists Production, Import, Consumption and Export Analysis

    • Table Poland Glucagon Like Peptide-1 (GLP-1) Agonists Production, Import, Consumption and Export Analysis

    • Table Russia Glucagon Like Peptide-1 (GLP-1) Agonists Production, Import, Consumption and Export Analysis

    • Table Switzerland Glucagon Like Peptide-1 (GLP-1) Agonists Production, Import, Consumption and Export Analysis

    • Table Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Glucagon Like Peptide-1 (GLP-1) Agonists Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Glucagon Like Peptide-1 (GLP-1) Agonists Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) Glucagon Like Peptide-1 (GLP-1) Agonists Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Glucagon Like Peptide-1 (GLP-1) Agonists Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Glucagon Like Peptide-1 (GLP-1) Agonists Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Glucagon Like Peptide-1 (GLP-1) Agonists Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Glucagon Like Peptide-1 (GLP-1) Agonists Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Types from 2014 to 2026

    • Table Germany Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Share by Types from 2014 to 2026

    • Table Germany Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by End-Users from 2014 to 2026

    • Table Germany Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Share by End-Users from 2014 to 2026

    • Table UK Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Types from 2014 to 2026

    • Table UK Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Share by Types from 2014 to 2026

    • Table UK Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by End-Users from 2014 to 2026

    • Table UK Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Share by End-Users from 2014 to 2026

    • Table France Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Types from 2014 to 2026

    • Table France Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Share by Types from 2014 to 2026

    • Table France Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by End-Users from 2014 to 2026

    • Table France Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Share by End-Users from 2014 to 2026

    • Table Italy Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Types from 2014 to 2026

    • Table Italy Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Share by Types from 2014 to 2026

    • Table Italy Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by End-Users from 2014 to 2026

    • Table Italy Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Share by End-Users from 2014 to 2026

    • Table Spain Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Types from 2014 to 2026

    • Table Spain Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Share by Types from 2014 to 2026

    • Table Spain Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by End-Users from 2014 to 2026

    • Table Spain Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Share by End-Users from 2014 to 2026

    • Table Poland Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Types from 2014 to 2026

    • Table Poland Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Share by Types from 2014 to 2026

    • Table Poland Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by End-Users from 2014 to 2026

    • Table Poland Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Share by End-Users from 2014 to 2026

    • Table Russia Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Types from 2014 to 2026

    • Table Russia Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Share by Types from 2014 to 2026

    • Table Russia Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by End-Users from 2014 to 2026

    • Table Russia Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Types from 2014 to 2026

    • Table Switzerland Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Share by Types from 2014 to 2026

    • Table Switzerland Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by End-Users from 2014 to 2026

    • Table Switzerland Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Share by End-Users from 2014 to 2026

    • Table Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Types from 2014 to 2026

    • Table Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Share by Types from 2014 to 2026

    • Table Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by End-Users from 2014 to 2026

    • Table Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark Glucagon Like Peptide-1 (GLP-1) Agonists Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Glucagon Like Peptide-1 (GLP-1) Agonists Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Glucagon Like Peptide-1 (GLP-1) Agonists Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Glucagon Like Peptide-1 (GLP-1) Agonists Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Glucagon Like Peptide-1 (GLP-1) Agonists Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium Glucagon Like Peptide-1 (GLP-1) Agonists Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Glucagon Like Peptide-1 (GLP-1) Agonists Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg Glucagon Like Peptide-1 (GLP-1) Agonists Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia Glucagon Like Peptide-1 (GLP-1) Agonists Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia Glucagon Like Peptide-1 (GLP-1) Agonists Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries Glucagon Like Peptide-1 (GLP-1) Agonists Market Volume and Growth Rate from 2014 to 2026

    • Table AstraZeneca Profiles

    • Table AstraZeneca Production, Value, Price, Gross Margin 2014-2019

    • Table AstraZeneca Product benchmarking

    • Table AstraZeneca Strategic initiatives

    • Table AstraZeneca SWOT analysis

    • Table Eli Lily Profiles

    • Table Eli Lily Production, Value, Price, Gross Margin 2014-2019

    • Table Eli Lily Product benchmarking

    • Table Eli Lily Strategic initiatives

    • Table Eli Lily SWOT analysis

    • Table Bristol-Myers Squibb Profiles

    • Table Bristol-Myers Squibb Production, Value, Price, Gross Margin 2014-2019

    • Table Bristol-Myers Squibb Product benchmarking

    • Table Bristol-Myers Squibb Strategic initiatives

    • Table Bristol-Myers Squibb SWOT analysis

    • Table GSK Profiles

    • Table GSK Production, Value, Price, Gross Margin 2014-2019

    • Table GSK Product benchmarking

    • Table GSK Strategic initiatives

    • Table GSK SWOT analysis

    • Table Amylin Profiles

    • Table Amylin Production, Value, Price, Gross Margin 2014-2019

    • Table Amylin Product benchmarking

    • Table Amylin Strategic initiatives

    • Table Amylin SWOT analysis

    • Table Sanofi Profiles

    • Table Sanofi Production, Value, Price, Gross Margin 2014-2019

    • Table Sanofi Product benchmarking

    • Table Sanofi Strategic initiatives

    • Table Sanofi SWOT analysis

    • Table Novo Nordisk Profiles

    • Table Novo Nordisk Production, Value, Price, Gross Margin 2014-2019

    • Table Novo Nordisk Product benchmarking

    • Table Novo Nordisk Strategic initiatives

    • Table Novo Nordisk SWOT analysis

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US